These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16923585)

  • 21. Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years.
    Matsue K; Fujiwara H; Iwama K; Kimura S; Yamakura M; Takeuchi M
    Ann Hematol; 2010 Mar; 89(3):291-7. PubMed ID: 19693498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema.
    Bos R; de Waal EG; Kuiper H; Hazenberg BP; Vellenga E
    Rheumatology (Oxford); 2011 Oct; 50(10):1925-6. PubMed ID: 21719421
    [No Abstract]   [Full Text] [Related]  

  • 23. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.
    Scott GB; Carter C; Parrish C; Wood PM; Cook G
    Cell Immunol; 2015 Sep; 297(1):1-9. PubMed ID: 26051632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment of extramedullary plasmacytoma of the cavernous sinus using a combination of intermediate dose of thalidomide and dexamethasone.
    Katodritou E; Speletas M; Pouli A; Tsitouridis J; Zervas K; Terpos E
    Acta Haematol; 2007; 117(1):20-3. PubMed ID: 17106187
    [No Abstract]   [Full Text] [Related]  

  • 26. The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).
    Terragna C; Remondini D; Martello M; Zamagni E; Pantani L; Patriarca F; Pezzi A; Levi G; Offidani M; Proserpio I; De Sabbata G; Tacchetti P; Cangialosi C; Ciambelli F; Viganò CV; Dico FA; Santacroce B; Borsi E; Brioli A; Marzocchi G; Castellani G; Martinelli G; Palumbo A; Cavo M
    Oncotarget; 2016 Mar; 7(9):9666-79. PubMed ID: 26575327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.
    Lokhorst HM; Schmidt-Wolf I; Sonneveld P; van der Holt B; Martin H; Barge R; Bertsch U; Schlenzka J; Bos GM; Croockewit S; Zweegman S; Breitkreutz I; Joosten P; Scheid C; van Marwijk-Kooy M; Salwender HJ; van Oers MH; Schaafsma R; Naumann R; Sinnige H; Blau I; Delforge M; de Weerdt O; Wijermans P; Wittebol S; Duersen U; Vellenga E; Goldschmidt H; ;
    Haematologica; 2008 Jan; 93(1):124-7. PubMed ID: 18166796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction therapy before transplantation in multiple myeloma: new strategies to achieve complete response.
    Wu KL; Sonneveld P
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):96-101. PubMed ID: 16231847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cranial nerve palsy in multiple myeloma and solitary plasmacytoma.
    Kashyap R; Kumar R; Kumar S
    Asia Pac J Clin Oncol; 2010 Dec; 6(4):251-5. PubMed ID: 21114773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lenalidomide is active for extramedullary disease in refractory multiple myeloma.
    Nakazato T; Mihara A; Ito C; Sanada Y; Aisa Y
    Ann Hematol; 2012 Mar; 91(3):473-4. PubMed ID: 21647581
    [No Abstract]   [Full Text] [Related]  

  • 31. Neoadjuvant therapy in a patient with clival plasmacytoma associated with multiple myeloma: a case report.
    Yamaguchi S; Terasaka S; Ando S; Shinohara T; Iwasaki Y
    Surg Neurol; 2008 Oct; 70(4):403-7. PubMed ID: 18291467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.
    Broijl A; Kersten MJ; Alemayehu WG; Levin MD; de Weerdt O; Vellenga E; Meijer E; Wittebol S; Tanis BC; Cornelisse PB; Stevens-Kroef M; Bos GM; Wijermans PW; Lokhorst H; Sonneveld P
    Haematologica; 2016 Apr; 101(4):e149-52. PubMed ID: 26659914
    [No Abstract]   [Full Text] [Related]  

  • 33. [How I treat... refractory multiple myeloma with thalidomide].
    Scerbo F; Matus G; Sautois B; Fillet G
    Rev Med Liege; 2000 Nov; 55(11):970-3. PubMed ID: 11195707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of response to thalidomide in plasmacytomas.
    Myers B; Grimley C; Crouch D; Dolan G
    Br J Haematol; 2001 Oct; 115(1):234. PubMed ID: 11722443
    [No Abstract]   [Full Text] [Related]  

  • 35. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.
    Cavo M; Zamagni E; Tosi P; Cellini C; Cangini D; Tacchetti P; Testoni N; Tonelli M; de Vivo A; Palareti G; Tura S; Baccarani M
    Haematologica; 2004 Jul; 89(7):826-31. PubMed ID: 15257934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma.
    Ribas C; Colleoni G; Almeida M; Duch CR; Ohashi C; Segreto R; Silva MR
    Acta Oncol; 2004; 43(2):215-6. PubMed ID: 15163174
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of cyclophosphamide-thalidomide-dexamethasone to bortezomib-cyclophosphamide-dexamethasone as induction therapy for multiple myeloma patients in Brazil.
    Vigolo S; Zuckermann J; Bittencourt RI; Silla L; Pilger DA
    Hematol Oncol Stem Cell Ther; 2017 Sep; 10(3):135-142. PubMed ID: 28636891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of thalidomide in multiple myeloma.
    Schwab C; Jagannath S
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):26-9. PubMed ID: 16879766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Very low doses of thalidomide as single agent in relapsed/refractory multiple myeloma.
    Guglielmelli T; Capella S; Saglio G
    Acta Haematol; 2006; 116(1):70-1. PubMed ID: 16809894
    [No Abstract]   [Full Text] [Related]  

  • 40. Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.
    Wu SY; Yeh YM; Chen YP; Su WC; Chen TY
    Ann Hematol; 2012 Nov; 91(11):1773-8. PubMed ID: 22706703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.